Mydayis
Narcolepsy, Depression, Attention Deficit Hyperactivity Disorder + 1 more
Treatment
2 FDA approvals
20 Active Studies for Mydayis
Treatment for
Narcolepsy
What is Mydayis
Amphetamine/Dextroamphetamine
The Generic name of this drug
Treatment Summary
Amphetamine is a strong stimulant drug that was discovered over 100 years ago. It is heavily regulated and only used for a few specific medical conditions. It is made up of two chemical compounds, alpha-methylphenethylamine, and has two forms of the same molecule (dextro- and levo-isomers). The first product of the drug was approved by the FDA in 1976. During World War II, amphetamine was used to keep soldiers awake, which led to an overproduction of it and its eventual sale on the black market.
Adderall
is the brand name
Mydayis Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Adderall
Amphetamine/Dextroamphetamine
1996
507
Approved as Treatment by the FDA
Amphetamine/Dextroamphetamine, also known as Adderall, is approved by the FDA for 2 uses such as Narcolepsy and Attention Deficit Hyperactivity Disorder .
Narcolepsy
Attention Deficit Hyperactivity Disorder
Used to treat Attention Deficit Hyperactivity Disorder (ADHD) in combination with Dextroamphetamine
Effectiveness
How Mydayis Affects Patients
Amphetamine increases levels of the brain chemicals noradrenaline and dopamine in a dose-dependent way, which can cause cardiovascular side effects. It has been reported to improve intelligence test scores, behavior and school performance in those with ADHD. It is commonly used in a 3:1 ratio of D:L forms. Amphetamine has a less clear effect on serotonin but could help with the depression and anxiety associated with ADHD. Taking amphetamine illicitly has been linked to paranoid states and misuse in those with depression.
How Mydayis works in the body
Amphetamine has a similar structure to catecholamine neurotransmitters and is taken into the presynaptic nerve terminals by attaching to three ions. This causes more amphetamine to be internalized. The amphetamine then competes with the other neurotransmitters, forcing them out of the presynaptic terminal and into the synapse. This process of release is more effective in the d-isomer form. In addition to this, amphetamine also inhibits the reuptake and monoamine oxidase, which increases the concentration of neurotransmitters. Lastly, amphetamine is a weak monoamine oxidase inhibitor which helps
When to interrupt dosage
The quantity of Mydayis is contingent upon the determined disease, such as Disease, Chronic Pain and Attention Deficit Hyperactivity Disorder. The measure of dosage fluctuates as per the method of administration (e.g. Oral or Tablet - Oral) featured in the table beneath.
Condition
Dosage
Administration
Attention Deficit Hyperactivity Disorder
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Chronic Pain
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Narcolepsy
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Depression
, 5.0 mg, 10.0 mg, 3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg, 2.5 mg/mL, 3.125 mg, 9.375 mg, 6.25 mg, 1.875 mg, 2.5 mg, 7.5 mg, 1.25 mg, 3.75 mg, 15.0 mg, 1.25 mg/mL, 18.75 mg, 25.0 mg, 7.26 mg, 12.11 mg, 2.42 mg, 9.69 mg, 14.53 mg, 4.84 mg, 20.0 mg, 60.0 mg, 40.0 mg, 30.0 mg
, Oral, Tablet - Oral, Tablet, Capsule, extended release, Capsule, extended release - Oral, Tablet, orally disintegrating - Oral, Tablet, orally disintegrating, Suspension, extended release - Oral, Suspension, extended release, Capsule, Capsule - Oral, Tablet, extended release, Tablet, extended release - Oral
Warnings
Mydayis has eight contraindications, making it inadvisable to use when encountering any of the conditions in the subsequent table.
Mydayis Contraindications
Condition
Risk Level
Notes
Agitation
Do Not Combine
advanced arteriosclerosis
Do Not Combine
Drug abuse
Do Not Combine
Hyperthyroidism
Do Not Combine
Hypertensive disease
Do Not Combine
symptomatic cardiovascular disease
Do Not Combine
Pulse Frequency
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Amphetamine/Dextroamphetamine may interact with Pulse Frequency
There are 20 known major drug interactions with Mydayis.
Common Mydayis Drug Interactions
Drug Name
Risk Level
Description
Clonidine
Major
The metabolism of Clonidine can be decreased when combined with Amphetamine.
Cyclophosphamide
Major
The metabolism of Cyclophosphamide can be decreased when combined with Amphetamine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Amphetamine.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Amphetamine.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Amphetamine.
Mydayis Toxicity & Overdose Risk
The average lethal dose of amphetamine is 6.4 mg/l. Taking too much of this drug can cause a dangerously high body temperature, impaired breathing, acid buildup in the body, kidney failure, liver damage, and loss of consciousness. Other symptoms may include agitation, aggression, extreme irritability, headaches, and hallucinations. There may also be problems with the heart such as an irregular heartbeat, heart damage, a heart attack, or a stroke. Additionally, amphetamine can cause abdominal pain, vomiting, diarrhea, cramps, anorexia, and bleeding in the digestive tract. Very high doses of 1-2g can be
Mydayis Novel Uses: Which Conditions Have a Clinical Trial Featuring Mydayis?
Currently, 710 active studies are exploring the potential of Mydayis to ameliorate symptoms of Depression, Disease and Narcolepsy.
Condition
Clinical Trials
Trial Phases
Narcolepsy
2 Actively Recruiting
Not Applicable, Phase 1
Attention Deficit Hyperactivity Disorder
63 Actively Recruiting
Not Applicable, Phase 3, Phase 4, Phase 1, Phase 2
Chronic Pain
0 Actively Recruiting
Depression
305 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Early Phase 1, Phase 4, Phase 3
Mydayis Reviews: What are patients saying about Mydayis?
5
Patient Review
9/25/2018
Mydayis for Attention Deficit Disorder with Hyperactivity
3.7
Patient Review
6/11/2019
Mydayis for Attention Deficit Disorder with Hyperactivity
1.7
Patient Review
12/13/2019
Mydayis for Attention Deficit Disorder with Hyperactivity
Patient Q&A Section about mydayis
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Is Mydayis a narcotic?
"Advise patients not to share MYDAYIS with others and to take steps to protect it from theft.
Controlled Substance Status/High Potential For Abuse And Dependence. Advise patients and their caregivers that MYDAYIS is a federally controlled substance because it has a high potential for abuse and dependence. Advise patients not to share MYDAYIS with others and to take steps to protect it from theft."
Answered by AI
Is Mydayis the same as Adderall?
"Both Mydayis and Adderall are central nervous system stimulants used to treat ADHD. However, Mydayis is formulated to last up to 16 hours, while Adderall only lasts for 12 hours."
Answered by AI
Can you get high off Mydayis?
"Mydayis is a Schedule II drug. It is highly addictive and has a high potential for abuse, like other amphetamines. Other Schedule II drugs include morphine and Vicodin. People abuse the drug for its pleasurable high."
Answered by AI
Which is better Vyvanse or Mydayis?
"There is no direct clinical comparative study between Mydayis and Vyvanse drugs, however, both drugs have been shown to be effective in treating ADHD in both adults and children in separate studies. Mydayis is used to treat children aged 13 years and older, while Vyvanse is used to treat children aged 6 years and older."
Answered by AI